Dr. Lao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
C451 Med Inn, 1500 East Med Center Dr
Ann Arbor, MI 48103Phone+1 734-615-1775- Is this information wrong?
Education & Training
University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Alabama Medical CenterResidency, Internal Medicine, 1998 - 2001
Icahn School of Medicine at Mount SinaiClass of 1998
Certifications & Licensure
MI State Medical License 2001 - 2026
AL State Medical License Active through 2001
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Dinaciclib in Treating Patients With Stage IV Melanoma Start of enrollment: 2009 Jul 01
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
- HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese, Asim Amin, Christopher D Lao, Valentina Boni, William H Sharfman, Jong Chul Park, Ma...> ;The Lancet. Oncology. 2024 Apr 9
- 11 citationsOverall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.Long, G., Stephen Hodi, F., Lipson, E., Schadendorf, D., Ascierto, P., Matamala, L., Salman, P., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H., Lao, C., Janoski De ...> ;NEJM Evidence. 2023 Apr 1
- 3 citationsHealth-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: R...Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, F Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen...> ;European Journal of Cancer. 2023 Jul 1
- Join now to see all
Journal Articles
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
Grant Support
- Development Of A Melanoma Chemoprevention ModelNational Cancer Institute2006–2010
- Phase I Single-Dose Safety And Pharmacokinetics Clinical Study Of ResveratrolNational Center For Research Resources2005–2006
- Feasibility Of Barrett?S Esophagus Chemoprev Through Eval Of Esophageal ResectNational Center For Research Resources2005
Professional Memberships
- Member
Hospital Affiliations
University of Michigan Medical CenterAnn Arbor, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
